Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/41764
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSobey C.G.en
dc.contributor.authorDrummond G.R.en
dc.date.accessioned2021-05-14T14:19:10Zen
dc.date.available2021-05-14T14:19:10Zen
dc.date.copyright2014en
dc.date.created20140904en
dc.date.issued2014-09-04en
dc.identifier.citationTrends in Endocrinology and Metabolism. 25 (9) (pp 452-463), 2014. Date of Publication: September 2014.en
dc.identifier.issn1043-2760en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/41764en
dc.description.abstractNADPH oxidases (NOXs) are reactive oxygen species (ROS)-generating enzymes implicated in the pathophysiology of vascular diseases such as hypertension and stroke. Endothelial cells express four NOX isoforms including the superoxide-generating enzymes NOX1, NOX2, and NOX5 and the hydrogen peroxide-generating enzyme NOX4. Studies on arteries from patients with coronary artery disease, and in animals with experimentally induced hypertension, diabetes, or atherosclerosis, suggest that NOX1, NOX2, and NOX5 promote endothelial dysfunction, inflammation, and apoptosis in the vessel wall, whereas NOX4 is by contrast vasoprotective in increasing nitric oxide bioavailability and suppressing cell death pathways. Based on these findings and promising preclinical studies with the NOX1/NOX2 antagonist, apocynin, we suggest that the field is poised for clinical evaluation of NOX inhibitors as therapeutics for cardiovascular disease. © 2014 Elsevier Ltd.en
dc.languageenen
dc.languageEnglishen
dc.publisherElsevier Inc. (E-mail: usjcs@elsevier.com)en
dc.relation.ispartofTrends in Endocrinology and Metabolismen
dc.titleEndothelial NADPH oxidases: Which NOX to target in vascular disease?.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.tem.2014.06.012en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid25066192 [http://www.ncbi.nlm.nih.gov/pubmed/?term=25066192]en
dc.identifier.source53253494en
dc.identifier.institution(Drummond, Sobey) Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, VIC, Australia (Drummond, Sobey) Department of Surgery, Monash Medical Centre, Southern Clinical School, Monash University, Clayton, VIC, Australiaen
dc.description.addressG.R. Drummond, Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, VIC, Australia. E-mail: grant.drummond@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2015 Elsevier B.V., All rights reserved.en
dc.subect.keywordsDiabetes Endothelial dysfunction Hyperlipidemia Hypertension Inflammation NADPH oxidases Reactive oxygen species Selective NOX1/2 inhibitors Vascular diseaseen
dc.identifier.authoremailDrummond G.R.; grant.drummond@monash.eduen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
Appears in Collections:Articles
Show simple item record

Page view(s)

18
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.